What if cancer isn’t unstoppable — but the immune system just isn’t fully awake? Scientists at the University of Southampton ...

T cells sit at the center of modern immunotherapy, yet many of the rules that govern their activation, differentiation, dysfunction (e.g., exhaustion), and ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

A new AI tool that models how variations in peptides change T cell receptor binding could help design immunotherapies with fewer off-target effects. Protein complexes that adorn the surface of T cells ...

Meet the Jekyll and Hyde of the immune system: activated CD8⁺ T cells. On June 24 in Nature Immunology, researchers led by Dorian McGavern at the National Institutes of Health introduce a granzyme ...

Treatment with nivolumab (Opdivo) had limited benefit in patients with multiple myeloma (MM) or non-Hodkin lymphoma (NHL) ...